Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyAetna Dermabrasion Chemical Peels Policy Update | …
    Ask Trek AI about this page
    CurrentAetnaPolicy 0251

    Dermabrasion, Chemical Peels, and Acne Surgery

    Customize your policy alerts

    Sign up for Aetna Policy 0251 alerts

    Get alerted when Policy 0251 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage policy governing medical necessity, investigational status, and cosmetic exclusions for dermabrasion, chemical peels, and acne surgery for Aetna members.

    Policy Summary
    PayerAetna
    PolicyDermabrasion, Chemical Peels, and Acne Surgery
    Policy CodePolicy 0251
    Change TypeNo material change
    Effective DateMay 26, 1998
    Last ReviewMay 15, 2023
    Next Review DateMar 14, 2024
    Key ActionObtain and document trial and failure of topical 5‑fluorouracil or imiquimod before dermabrasion or medium/deep chemical peels for actinic keratoses unless contraindicated.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    15+Min lesions for medium/deep peels
    6 monthsTime after isotretinoin to avoid dermabrasion
    1,300,000US chemical peels (2016)
    05/15/2023Policy last review

    Coverage Criteria

    Coverage Criteria

    Aetna considers the following procedures medically necessary or investigational as specified below. Consolidated coverage criteria, investigational statements, and cosmetic exclusions are provided.

    Dermabrasion — Experimental/Investigational: Dermabrasion and microdermabrasion are considered investigational (effectiveness not established) for the following indications:
    • Active acne (dermabrasion may increase inflammation associated with active acne);
    • Diffuse silicone granuloma;
    • Dyschromias;
    • Keloids;
    • Melasma;
    • Vitiligo;
    • All other indications not listed as medically necessary or as cosmetic in this section.
    Chemical peels — Experimental/Investigational: Chemical peels are considered investigational for active acne and for all other indications not listed as medically necessary or cosmetic.
    Other procedures considered investigational include:
    • Cryoslush therapy (solid CO2 mixed with acetone) and liquid nitrogen therapy for acne;
    • Fractional radiofrequency (including fractional micro-plasma radiofrequency) for treatment of acne scars (insufficient high-quality evidence for first-line use);
    • Micro-needling for acne scars and other dermatologic indications (evidence limited; considered investigational for indications not otherwise listed as medically necessary).
    Cosmetic Exclusions (Not Medically Necessary): The following are considered cosmetic and therefore not medically necessary:
    • Dermabrasion for scar revision or removal of acne scars (post-acne scarring);
    • Chemical peels for acne scarring, melasma, skin wrinkling, or lentigines;
    • Scar injection or any treatment intended solely to smooth or reduce visible acne scarring.
    Coverage Notes and Limitations:
    • Dermabrasion is contraindicated in patients with active acne and may exacerbate inflammation; dermabrasion performed within 6 months of isotretinoin (Accutane) therapy has been associated with increased scarring.
    • For actinic keratoses, chemical peeling is appropriate only when numerous lesions make individual lesion treatment impractical (Aetna threshold: generally 15 or more lesions).
    • Where listed as investigational, procedures are not covered because effectiveness has not been established.
    • Exceptions to cosmetic exclusions (e.g., scar revision) may be subject to specific plan benefit provisions; review applicable plan documents.

    Coding

    Dermabrasion CPT CodesCPTCovered
    15780Dermabrasion; total face
    15781Dermabrasion; segmental, face
    15782Dermabrasion; regional, other than face
    15783Dermabrasion; superficial, any site (e.g., tattoo removal)
    Chemical Peel CPT CodesCPT
    15789Chemical peel, facial; dermal
    15793Chemical peel, nonfacial; dermal
    15788Chemical peel, facial; epidermal
    15792Chemical peel, nonfacial; epidermal
    17360Chemical exfoliation for acne
    Acne Surgery / Intralesional Injection CPT CodesCPTCovered
    10040Acne surgery (e.g., marsupialization, opening or removal of multiple milia, comedones, cysts, pustules)
    11900Injection, intralesional; up to and including 7 lesions
    11901Injection, intralesional; more than 7 lesions
    HCPCS Drugs for Intralesional InjectionHCPCSCovered
    J3301Injection, triamcinolone acetonide, not otherwise specified, 10 mg
    ICD-10 Codes (examples covered and not covered)ICD-10
    C44.01Basal cell carcinoma (example ICD-10 listed)
    L57.0Actinic keratosis
    L70.0-L70.9Acne (listed as ICD-10 not covered for some indications)
    L90.5Scar conditions and fibrosis of skin [includes acne scarring]
    Not covered CPT CodesCPTNot Covered
    17340Cryotherapy (CO2, slush, liquid N2) for acne
    Procedures without specific CPT codes / not covered for listed indicationsmixedNot Covered
    Fractional radiofrequencyFractional radiofrequency - no specific CPT code listed
    Fractional micro-plasma radiofrequencyFractional micro-plasma radiofrequency - no specific CPT code listed
    Micro-needlingMicro-needling - no specific CPT code listed

    Provider Actions and Documentation

    Prior Authorization

    Prior authorization recommended for low-evidence interventions

    Prior authorization is recommended for interventions with limited or low-quality evidence (for example, some fractional radiofrequency modalities and certain microneedling or specific chemical peel indications) — obtain prior authorization when clinical effectiveness must be demonstrated.

    • Examples include newer fractional radiofrequency (FRF) devices and specific microneedling combinations where high-quality comparative evidence is lacking.
    Prior Authorization

    Prior authorization — no specifics in this part

    This section of the policy does not list additional, specific prior authorization CPT/HCPCS codes or operational rules. Providers should refer to the payer’s Clinical Policy Bulletin or benefits portal for plan-specific prior authorization procedures and up-to-date code lists.

    • When submitting requests, include the clinical rationale and supporting documentation described below.

    Background

    Dermabrasion removes the epidermis and superficial dermis to allow re‑epithelialization and improve skin contour. The technique—using mechanical abrasion (wire brush or diamond fraise) or laser resurfacing—is most appropriate for superficial facial lesions and is used primarily for cosmetic resurfacing rather than active inflammatory acne management.

    Definitions

    Dermabrasion
    DefinitionA procedure that removes the epidermis and superficial dermis using mechanical abrasion (e.g., wire brush or diamond fraise) or laser to resurface skin.
    MechanismRemoves epidermal surface allowing re-epithelialization from underlying skin to improve contour
    Common instrumentsWire brush, diamond fraise, argon laser, ultrapulse CO2 laser, flashlamp‑pumped pulsed dye laser
    Chemical peel depth categories
    Superficial peels — examples/agents10–35% trichloroacetic acid (TCA), resorcin, Jessner's solution, Retin‑A, 5‑FU, azelaic acid, alpha hydroxy acids (glycolic, lactic)
    Medium peels — examples/agents~50% TCA or lower concentrations of TCA combined with Jessner's solution, 5‑FU, or carbon dioxide cryotherapy

    Revision History

    2023-05-15policy_reviewLatest

    Policy last reviewed on 05/15/2023 (clinical content reviewed).

    1998-05-26policy_effective

    Policy originally became effective on 05/26/1998.

    2024-03-14next_scheduled_review

    Next scheduled policy review on 03/14/2024.

    Policy Summary
    PayerAetna
    PolicyDermabrasion, Chemical Peels, and Acne Surgery
    Policy CodePolicy 0251
    Change TypeNo material change
    Effective DateMay 26, 1998
    Last ReviewMay 15, 2023
    Next Review DateMar 14, 2024
    Key ActionObtain and document trial and failure of topical 5‑fluorouracil or imiquimod before dermabrasion or medium/deep chemical peels for actinic keratoses unless contraindicated.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and DocumentationBackgroundDefinitionsRevision History
    Denial Risk

    Evidence limitations may trigger denial

    Insufficient or low-quality evidence (small, underpowered trials; lack of superiority over placebo/sham; or outcomes not clinically meaningful) may lead to denial of coverage for the requested procedure.

    • Evidence gaps frequently noted for FRF and some microneedling approaches.
    • Denials may be issued when the submitted literature or clinical data do not establish effectiveness for the requested indication.
    Denial Risk

    Evidence insufficiency risk

    Requests that rely on limited, inconsistent, or non-comparative data risk non-coverage. If the clinical record and cited literature do not meet the policy’s requirement for established effectiveness for the requested indication, prior authorization may be denied.

    • Provide comparative trials or well-controlled studies when available.
    • Describe why alternative, established treatments are not appropriate for the member.
    Documentation Required

    Required clinical documentation

    Clinical documentation must support the medical necessity criteria for the requested procedure. Include lesion counts, distribution, prior therapies and responses, and any contraindications to standard topical treatments.

    • For dermabrasion or medium/deep chemical peels for actinic keratoses: document number and distribution of lesions (e.g., ≥15 actinic keratoses) and prior trial and failure of topical 5‑FU or imiquimod, unless contraindicated.
    • For dermabrasion for superficial basal cell carcinoma: document that conventional removal methods (cryotherapy, curettage, excision) are impractical due to number/distribution of lesions.
    Documentation Required

    Documentation for intralesional injections

    When intralesional corticosteroids are used, document the lesion type, size, concentration and volume injected, number of injections, and that the patient was counseled about potential local and systemic adverse effects.

    • Specify steroid agent and concentration (e.g., triamcinolone acetonide 0.63–2.5 mg/mL) and injection technique (needle gauge, volume per lesion).
    • Document monitoring for and counseling about local atrophy, hypopigmentation, telangiectasias and potential systemic absorption.
    Documentation Required

    Suggested documentation

    Include objective measures of treatment response and procedural details in the record: modality used, number and timing of sessions, photographic documentation, validated outcome scales when available (e.g., GAIS), and adverse events.

    • Pre- and post-treatment standardized photos with dates.
    • Record number of treatment sessions, device parameters (energy settings, applicator tip), and concurrent or prior combination therapies (e.g., PDT, topical agents).
    • Use validated or objective assessments where feasible (Global Aesthetic Improvement Scale, scar grading).
    Step Therapy

    Stepwise use of procedural acne therapies

    Document stepwise use of procedural acne therapies per clinical guidance. Consider comedo removal or intralesional corticosteroids as adjuncts or for lesions resistant to medical therapy; surgical procedures (incision/drainage, punch debridement, unroofing) are appropriate for specified stages of hidradenitis suppurativa and selected acne lesions.

    • Comedo removal may be helpful for comedones resistant to topical/systemic therapies.
    • Intralesional steroid injection is an option for large inflammatory nodules; document trials of topical/systemic therapy and rationale for procedural intervention.
    Note

    Consideration of prior therapies

    Consider prior and concurrent therapies when requesting procedures for scarring or acne. Microneedling and FRF are often used alone or in combination with photodynamic therapy, topical agents, or other minimally invasive treatments; document prior response and rationale for combination therapy.

    • List prior treatments (topical, systemic, laser, PDT) and outcomes.
    • If combination therapy is planned, describe the contribution of each modality and expected incremental benefit over single-modality treatment.
    Note

    Policy history

    Policy history, including last review and next review dates, should be referenced for the most current policy version and any updates affecting prior authorization or documentation requirements.

    • Effective date: 05/26/1998.
    • Last review: 05/15/2023. Next review: 03/14/2024.
    • Refer to the Clinical Policy Bulletin and review history for plan-specific guidance.
    Deep peels — examples/agentsBaker's phenol or 50–70% TCA
    Active acne — definition and dermabrasion contraindication
    DefinitionAcne with present inflammation (inflammatory lesions) treated with oral/topical antibiotics and retinoids
    Dermabrasion noteDermabrasion is contraindicated for active acne as it may exacerbate inflammation; procedures within 6 months of isotretinoin are associated with increased scarring
    Typical treatments for active acneSystemic and topical antibiotics, retinoids (e.g., isotretinoin, tretinoin)
    Chemical peeling (chemo-exfoliation)
    DefinitionChemical peeling (chemo‑exfoliation) is targeted cutaneous ablation using caustic agents to achieve predictable depth of dermal/epidermal injury for skin improvement
    PurposeUsed to destroy superficial skin layers to allow regeneration and improved appearance; applied for cosmetic indications and for numerous dermatologic uses
    Clinical noteClassification by targeted depth (superficial, medium, deep) determines agent choice and potential therapeutic versus cosmetic intent
    Acne inversa (hidradenitis suppurativa) staging
    Stage IAbscess formation (single or multiple) without sinus tracts and scarring
    Stage IIRecurrent abscesses with sinus tracts and scarring; single or multiple widely separated lesions
    Stage IIIDiffuse or almost diffuse involvement or multiple interconnected sinus tracts and abscesses across the entire area
    Fractional radiofrequency (FRF)
    DefinitionNon‑ablative radiofrequency that delivers thermal micro‑injury to the dermis to stimulate remodeling and collagen production for acne scar improvement
    Clinical effectProduces small thermal wounds in the dermis leading to collagen remodeling; expected improvement over multiple sessions (e.g., 3–4 sessions)
    Adverse effectsTransient pain, erythema, scabbing; long‑term sustainability of responses not well established
    Fractional radiofrequency (FRF) — device description
    Device descriptionDevice‑based treatment delivering fractionated radiofrequency energy (including micro‑plasma RF) to the skin using applicator tips (e.g., 80‑pin and 160‑pin tips)
    Treatment course in cited studySeries of 3 FRF treatments to full face, each 4 weeks apart; applicator energy varied by pin configuration
    Assessment methodsEvaluated by blinded photographic GAIS and patient satisfaction questionnaires
    Micro-needling (MN)
    DefinitionA minimally invasive procedure using sterile microneedles to create controlled dermal micro‑injury to stimulate collagen remodeling and facilitate transdermal delivery of topical agents
    IndicationsUsed for acne scars, striae, vitiligo adjunctive therapy, and other dermatologic indications
    Procedure characteristicsTypically performed in 1–6 monthly sessions; low risk of severe adverse events but standardized protocols and more RCTs are needed
    Microneedling — evidence for acne scars
    Evidence summaryMultiple systematic reviews and prospective studies have evaluated microneedling for acne scars; results suggest improvement but many studies are small or heterogeneous
    Clinical findingsLarge prospective series reported substantial improvement (e.g., many patients achieving ≥50% improvement after ~2.5 treatments), but Level of Evidence often IV
    Evidence gapAuthors conclude that more double‑blinded, randomized, controlled trials and standardized protocols are needed to draw definitive conclusions
    Fractional radiofrequency / Cryotherapy — therapies discussed
    Modalities discussedFractional radiofrequency (including fractional micro‑plasma RF) and cryotherapy (liquid nitrogen) have been studied for acne scarring and acne vulgaris
    Study qualityStudies are often small, heterogeneous, and limited in follow‑up; effectiveness and long‑term durability are not well established
    Clinical implicationThese therapies may require individualized justification or prior authorization due to limited high‑quality evidence